Invitrogen™ Envafolimab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA542259

Catalog No. PIMA542259

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Envafolimab (KN035) is the world's first new fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc. Compared with the PD-1/PD-L1 antibodies currently on the market and under development, it has a distinct advantage . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and fast tumor penetration, which can improve the compliance of tumor patients and improve the quality of life of patients, which is in line with the future trend of long-term management of tumors as chronic diseases.

Specifications

• Antigen: Envafolimab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: KN-035
• Immunogen: Human CD274/PD-L1/B7-H1.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid

• Applications: ELISA, SDS-Page
• Concentration: 2.8 mg/mL
• Formulation: PBS with no preservative; pH 7.4
• Host Species: Human
• Purification Method: Protein A/G
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Target Molecule: Chemical